Table 1.
Baseline characteristics of SPRINT participants with CKD by PTH quartiles
| Characteristic | PTH Q1 | PTH Q2 | PTH Q3 | PTH Q4 | ||
|---|---|---|---|---|---|---|
| n=653 | n=629 | n=590 | n=614 | |||
| PTH range, pg/ml | 4–35 | 36–48 | 49–67 | 68–409 | ||
| Age, yr, mean±SD | 73 (9) | 74 (8) | 73 (8) | 72 (10) | ||
| Men, n (%) | 365 (59) | 410 (65) | 347 (59) | 345 (56) | ||
| Race, n (%) | ||||||
| White | 535 (82) | 493 (78) | 412 (70) | 328 (53) | ||
| Black | 103 (16) | 119 (19) | 158 (27) | 268 (43.7) | ||
| Other | 15 (2) | 17 (3) | 20 (3) | 18 (3) | ||
| Smoking, n (%) | ||||||
| Current | 73 (11) | 50 (8) | 38 (6) | 58 (9) | ||
| Former | 288 (44) | 282 (45) | 275 (47) | 268 (44) | ||
| Never | 292 (45) | 297 (47) | 277 (47) | 288 (47) | ||
| Prevalent cardiovascular disease, n (%) | 160 (25) | 162 (26) | 144 (24) | 159 (26) | ||
| Prevalent heart failure, n (%) | 27 (4) | 31 (5) | 38 (6) | 58 (9) | ||
| eGFR, ml/min per 1.73 m2, mean±SD | 48 (9) | 48 (9) | 46 (10) | 30 (12) | ||
| eGFR categories, n (%) | ||||||
| 45–60 ml/min per 1.73 m2 | 453 (69) | 426 (68) | 347 (59) | 251 (41) | ||
| 30–44 ml/min per 1.73 m2 | 171 (27) | 175 (28) | 197 (33) | 227 (37) | ||
| <30 ml/min per 1.73 m2 | 29 (4) | 28 (4) | 46 (8) | 136 (22) | ||
| Urine albumin-to-creatinine, median (IQR) | 12 (6–33) | 13 (6–37) | 15 (7–50) | 28 (10–107) | ||
| Urine albumin-to-creatinine >30 mg/g, n (%) | 193 (30) | 198 (32) | 211 (36) | 304 (50) | ||
| Systolic BP, mm Hg, mean±SD | 139 (16) | 134 (17) | 140 (16) | 140 (17) | ||
| Diastolic BP, mm Hg, mean±SD | 73 (12) | 73 (12) | 75 (12) | 76 (13) | ||
| No. of antihypertensives, mean±SD | 2.0±1.0 | 2.1±1.0 | 2.2±1.0 | 2.3±1.0 | ||
| Body mass index, kg/m2, mean±SD | 28.6 (5.3) | 29.3 (5.4) | 29.8 (5.8) | 30.4 (6.8) | ||
| Serum total cholesterol, mg/dl, mean±SD | 183 (40) | 183 (40) | 184 (39) | 182 (40) | ||
| Serum HDL cholesterol, mg/dl, mean±SD | 53 (15) | 52 (14) | 52 (14) | 53 (15) | ||
| Calcium, mg/dl, mean±SD | 9.7 (0.5) | 9.6 (0.4) | 9.6 (0.4) | 9.5 (0.7) | ||
| Phosphate, mg/dl, mean±SD | 3.7 (0.5) | 3.5 (0.5) | 3.5 (0.5) | 3.5 (0.6) | ||
| FGF23, pg/ml, median (IQR) | 63 (51–83) | 63 (51–79) | 66 (52–86) | 76 (56–104) | ||
SPRINT, Systolic Blood Pressure Intervention Trial; PTH, parathyroid hormone; Q, quartile; IQR, interquartile range; FGF23, fibroblast growth factor-23.